Danish universities forging ties with Japan

Danish researchers are set to receive funding from the Japanese medical group, Shionogi. Five Danish universities have joined forces with Shionogi in order to carry out a number of research projects, reports the Ministry of Foreign Affairs.

From the autumn of 2012 the universities of Aalborg, Aarhus, Copenhagen, Southern Denmark and the Technical University will be able to apply to the Japanese company, Shionogi, for funding for pharmaceutical research projects. Denmark has been selected due to the outstanding competences of its universities, which contribute to the Danish pharmaceutical industry’s strong international position.

Isao Teshirogi, CEO of Shionogi, praises the Danish education system and explains why the Japanese firm is investing in Denmark.

- Denmark has Medicon Valley, which is one of the best biotech clusters in Europe and many biotech enterprises are actively promoting research and development together with universities and academic institutions. We are honoured to have this opportunity to engage in collaborative research projects. We expect to create international competences by interacting with researchers with pioneering knowledge. By exploiting this opportunity, we will be able to significantly enhance our global development based on our research and development, says Isao Teshirogi.

Copenhagen Capacity and Invest in Denmark have been jointly working to attract the Japanese actor to Denmark for several years.

- It is good news for Danish universities and the Danish pharmaceutical sector when we are able to establish permanent research links with leading international groups such as Shionogi. Invest in Denmark and Copenhagen Capacity have cooperated on marketing Danish Life Science competences in Japan for many years, a marketing effort that is now paying off in terms of this collaborative research with Danish universities, says Ruth Klyver, Business Development Manager at Copenhagen Capacity.

Shionogi has its headquarters in Osaka in Japan and employs 6000 people globally. The company focuses on a range of therapeutic areas including the treatment of pain, contagious diseases, diabetes, HIV and cancer.

For additional information, please contact

Ruth Klyver (Copenhagen Capacity)
Business Development Manager
E-mail:
rk@copcap.com

Telephone: +45 61 62 64 66

Theresa Høgenhaug (Invest in Denmark)
Regional Projektleder
E-mail: therho@um.dk
Telephone: +45 41 26 20 88